Qian Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qian Guo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Xiao Wang
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications Yingying Guo
Cardiometabolic Medicine Center Fuwai Hospital National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
2 shared publicationsBin Que
Division of Cardiology, Beijing Anzhen Hospital, National Clinical Research Center for Cardiovascular Diseases Capital Medical University Beijing China
1 shared publication- Bin Que
Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
1 shared publication - Caixia Guo
Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China
1 shared publication - Deyong Long
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (7)
Longitudinal Sleep Patterns and Risk of Type 2 Diabetes Mellitus
Aims: Evidence relating sleep characteristics to type 2 diabetes mellitus (T2DM) has largely been based on single assessments. We examined whether transitions in a multidimensional healthy sleep score between two assessments were associated with incident T2DM and explored the relationship of the triglyceride‐glucose (TyG) index to this association. Materials and Methods: We conducted a landmark analysis among 60,249 UK Biobank participants with sleep assessed at visits 1 and 2. Visit 2 was defined as time zero for follow‐up. Sleep pattern transitions were classified according to poor, intermediate, or healthy sleep status at each assessment. Cox proportional hazards models were used to estimate associations with incident T2DM. TyG analysis was treated as exploratory. Results: During a median follow‐up of 4.2 years, 1284 incident T2DM cases occurred. Compared with stable healthy sleep, stable poor sleep was associated with higher risk (hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.32–3.27). Baseline‐stratified analyses did not show higher risk for improvement from poor or intermediate sleep relative to remaining in the same baseline category. The full‐cohort spline showed evidence of nonlinearity ( p for nonlinearity < 0.001), and TyG analyses were exploratory. Conclusions: Sleep pattern transitions between the two assessments were associated with incident type 2 diabetes, and the association differed by baseline sleep status. Repeated sleep assessment may complement single‐time‐point evaluation in understanding the role of sleep in diabetes risk.
- 12 October 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (7)
Open AccessLongitudinal Sleep Patterns and Risk of Type 2 Diabetes Mellitus
Aims: Evidence relating sleep characteristics to type 2 diabetes mellitus (T2DM) has largely been based on single assessments. We examined whether transitions in a multidimensional healthy sleep score between two assessments were associated with incident T2DM and explored the relationship of the triglyceride‐glucose (TyG) index to this association. Materials and Methods: We conducted a landmark analysis among 60,249 UK Biobank participants with sleep assessed at visits 1 and 2. Visit 2 was defined as time zero for follow‐up. Sleep pattern transitions were classified according to poor, intermediate, or healthy sleep status at each assessment. Cox proportional hazards models were used to estimate associations with incident T2DM. TyG analysis was treated as exploratory. Results: During a median follow‐up of 4.2 years, 1284 incident T2DM cases occurred. Compared with stable healthy sleep, stable poor sleep was associated with higher risk (hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.32–3.27). Baseline‐stratified analyses did not show higher risk for improvement from poor or intermediate sleep relative to remaining in the same baseline category. The full‐cohort spline showed evidence of nonlinearity ( p for nonlinearity < 0.001), and TyG analyses were exploratory. Conclusions: Sleep pattern transitions between the two assessments were associated with incident type 2 diabetes, and the association differed by baseline sleep status. Repeated sleep assessment may complement single‐time‐point evaluation in understanding the role of sleep in diabetes risk.
- 24 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6950-6958
Prognostic Implications of Coronary Microvascular Dysfunction in ST ‐Elevation Myocardial Infarction by Obesity Status
Aims: This study aimed to assess the association of coronary microvascular dysfunction (CMD) assessed by the angiography‐derived index of microcirculatory resistance (angio‐IMR) with long‐term cardiovascular outcomes in ST‐elevation myocardial infarction (STEMI) patients stratified by obesity categories. Materials and Methods: In this multicentre prospective cohort, STEMI patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled. Patients were stratified by obesity categories (healthy weight: BMI < 24 kg/m 2 ; overweight: 24–28 kg/m 2 ; obesity: ≥ 28 kg/m 2 ). CMD was defined as angio‐IMR > 40 U. Results: Of 497 STEMI patients, CMD prevalence was comparable across BMI groups ( p = 0.875). The cumulative incidence of MACCE was significantly higher in the CMD group than in the non‐CMD group among patients with obesity (33.3% vs. 15.0%, log‐rank p = 0.016), but not among those with overweight (19.6% vs. 15.9%, log‐rank p = 0.565) and healthy weight (20.7% vs. 17.4%, log‐rank p = 0.673). CMD independently predicted MACCE in obesity (adjusted HR; p = 0.020), with consistent results for continuous angio‐IMR (adjusted HR 1.03, p < 0.001). No associations existed in patients with overweight or healthy weight. Additionally, CMD was associated with a higher prevalence of intramyocardial haemorrhage exclusively in obesity (adjusted OR 4.40, p = 0.003) and overweight (adjusted OR 2.65, p = 0.007). Conclusion: CMD assessed by angio‐IMR is an independent predictor of MACCE in STEMI patients with obesity, but not those without obesity. Patients with obesity and STEMI who have CMD may represent a high‐risk subgroup for future trials of microvascular‐protective therapies.
- 24 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6950-6958
Prognostic Implications of Coronary Microvascular Dysfunction in ST ‐Elevation Myocardial Infarction by Obesity Status
Aims: This study aimed to assess the association of coronary microvascular dysfunction (CMD) assessed by the angiography‐derived index of microcirculatory resistance (angio‐IMR) with long‐term cardiovascular outcomes in ST‐elevation myocardial infarction (STEMI) patients stratified by obesity categories. Materials and Methods: In this multicentre prospective cohort, STEMI patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled. Patients were stratified by obesity categories (healthy weight: BMI < 24 kg/m 2 ; overweight: 24–28 kg/m 2 ; obesity: ≥ 28 kg/m 2 ). CMD was defined as angio‐IMR > 40 U. Results: Of 497 STEMI patients, CMD prevalence was comparable across BMI groups ( p = 0.875). The cumulative incidence of MACCE was significantly higher in the CMD group than in the non‐CMD group among patients with obesity (33.3% vs. 15.0%, log‐rank p = 0.016), but not among those with overweight (19.6% vs. 15.9%, log‐rank p = 0.565) and healthy weight (20.7% vs. 17.4%, log‐rank p = 0.673). CMD independently predicted MACCE in obesity (adjusted HR; p = 0.020), with consistent results for continuous angio‐IMR (adjusted HR 1.03, p < 0.001). No associations existed in patients with overweight or healthy weight. Additionally, CMD was associated with a higher prevalence of intramyocardial haemorrhage exclusively in obesity (adjusted OR 4.40, p = 0.003) and overweight (adjusted OR 2.65, p = 0.007). Conclusion: CMD assessed by angio‐IMR is an independent predictor of MACCE in STEMI patients with obesity, but not those without obesity. Patients with obesity and STEMI who have CMD may represent a high‐risk subgroup for future trials of microvascular‐protective therapies.
- Open Access
- 28 July 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (7) , 33439
Association of Obstructive Sleep Apnea With Cardiovascular Events in Acute Coronary Syndrome Patients With or Without Excessive Daytime Sleepiness: A Prospective Cohort Study
Background: Excessive daytime sleepiness (EDS) is a commonly observed symptom in people with obstructive sleep apnea (OSA). However, the impact of EDS on the outcome of patients with acute coronary syndrome (ACS) and OSA is not known. Therefore, this study aimed to investigate the association between OSA and cardiovascular events in ACS patients with or without EDS. Methods: This cohort study prospectively enrolled eligible ACS patients who underwent cardiorespiratory polygraphy during hospitalization between June 2015 and January 2020. We defined OSA as an apnea–hypopnea index (AHI) ≥15 events per h. EDS was described as having an Epworth Sleepiness Scale score ≥10. Major adverse cerebrovascular and cardiovascular events (MACCEs) were the primary outcome and included cardiovascular death, stroke, myocardial infarction, ischemia-driven revascularization, or hospitalization for heart failure or unstable angina. Results: The final study cohort comprised 1154 participants, of whom 398 (34.5%) had EDS, and 607 (52.6%) had OSA. During the median follow-up period of 2.9 years (interquartile range 1.5, 3.6), OSA was associated with a significantly increased risk of MACCEs in patients without EDS (adjusted hazard ratio (HR) = 1.42, 95% CI: 1.01–2.02, p = 0.046), but not in patients with EDS (adjusted hazard ratio HR = 1.05, 95% CI: 0.67–1.66, p = 0.84). Conclusions: OSA was associated with an elevated risk of MACCEs In ACS patients without EDS but not those with EDS. Therefore, screening for OSA should be performed in ACS patients without EDS, and future trials should prioritize such high-risk patients. Clinical Trial Registration: NCT03362385, https://clinicaltrials.gov/study/NCT03362385.
- 28 July 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (7) , 33439
Open AccessAssociation of Obstructive Sleep Apnea With Cardiovascular Events in Acute Coronary Syndrome Patients With or Without Excessive Daytime Sleepiness: A Prospective Cohort Study
Background: Excessive daytime sleepiness (EDS) is a commonly observed symptom in people with obstructive sleep apnea (OSA). However, the impact of EDS on the outcome of patients with acute coronary syndrome (ACS) and OSA is not known. Therefore, this study aimed to investigate the association between OSA and cardiovascular events in ACS patients with or without EDS. Methods: This cohort study prospectively enrolled eligible ACS patients who underwent cardiorespiratory polygraphy during hospitalization between June 2015 and January 2020. We defined OSA as an apnea–hypopnea index (AHI) ≥15 events per h. EDS was described as having an Epworth Sleepiness Scale score ≥10. Major adverse cerebrovascular and cardiovascular events (MACCEs) were the primary outcome and included cardiovascular death, stroke, myocardial infarction, ischemia-driven revascularization, or hospitalization for heart failure or unstable angina. Results: The final study cohort comprised 1154 participants, of whom 398 (34.5%) had EDS, and 607 (52.6%) had OSA. During the median follow-up period of 2.9 years (interquartile range 1.5, 3.6), OSA was associated with a significantly increased risk of MACCEs in patients without EDS (adjusted hazard ratio (HR) = 1.42, 95% CI: 1.01–2.02, p = 0.046), but not in patients with EDS (adjusted hazard ratio HR = 1.05, 95% CI: 0.67–1.66, p = 0.84). Conclusions: OSA was associated with an elevated risk of MACCEs In ACS patients without EDS but not those with EDS. Therefore, screening for OSA should be performed in ACS patients without EDS, and future trials should prioritize such high-risk patients. Clinical Trial Registration: NCT03362385, https://clinicaltrials.gov/study/NCT03362385.